Published in Obesity and Diabetes Week, January 1st, 2007
Lilly reconfirmed its 2006 sales guidance of growing at approximately the low end of 7 to 9% and reiterated its 2006 earnings guidance of $3.10 to $3.20 per share on an adjusted basis, or $2.74 to $2.84 on a reported basis, excluding any other future, material unusual items. Lilly anticipates 2007 sales growth in the high single or low double digits and earnings of $3.25 to $3.35 per share on a reported basis,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.